Jefferies analyst Roger Song upgraded BioAge Labs (BIOA) to Buy from Hold with a price target of $62, up from $9. The firm, which updated its thesis on BGE-102 and market potential in ASCVD/ophthalmology, views ‘102 as potentially best-in-class, validated by “robust” Phase 1 data. The firm sees multiple value creation points for BioAge during 2026, the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOA:
- BioAge Labs price target raised to $23 from $12 at Morgan Stanley
- BioAge Labs initiated with an Overweight at Piper Sandler
- BioAge Labs: De-Risked NLRP3 Program and 2026 Clinical Catalysts Underpin Overweight/Buy Rating
- BioAge Labs Announces Upsized Public Equity Offering
- Closing Bell Movers: Netflix down 5% after soft guidance